AI assistant
Niagen Bioscience, Inc. — Director's Dealing 2012
Jul 5, 2012
32418_dirs_2012-07-05_0b75005d-3680-4e62-952a-253b2024d0ee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2012-07-03
Reporting Person: Honig Barry C (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-07-03 | Common Stock | P | 8506 | $0.67 | Acquired | 3186366 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4004959 | Direct |
Footnotes
F1: Indirect ownership includes (i) 230,000 Shares owned by GRQ Consultants, Inc. Defined Benefits Plan for the benefit of the Reporting Person; (ii) 852,795 Shares owned by GRQ Consultants, Inc. 401K of which the Reporting Person is the beneficiary; and (iii) 2,103,571 Shares owned by GRQ Consultants Inc. Roth 401K FBO Renee Honig, the Reporting Person's spouse, of which the Reporting Person has voting and investment power and disclaims beneficial ownership. GRQ Consultants, Inc. 401K is the entity that purchased the 8,506 shares reported on this form.